Parkinson's Disease Flashcards
*The 3 cardinal signs of PD are: __, __, __.
Akinesia/Bradykinesia
Rigidity
Tremors
*Subjective sense of weakness, loss of dexterity, difficulty using kitchen tools, loss of facial expression, reduced blinking, difficulty getting out of bed/chair, difficulty turning while walking.
These are a sign of __.
Akinesia/Bradykinesia (Cardinal sign of PD)
*A patient describes “ratchet”-like stiffness (cogwheel rigidity); also leadpipe rigidity.
These are a sign of __.
Rigidity (Cardinal sign of PD)
*Resting tremors that disappears with movement), but increases with stress. A pill rolling movement around 4-8hz may be observed.
These are a sign of __.
Tremors (Cardinal sign of PD)
A patient presenting with idiopathic PD will usually have: \_\_ features Positive response to \_\_/\_\_ \_\_ progression of PD No presence of \_\_ or \_\_
- Asymmetric
- levodopa/apomorphine
- Slow
- postural instability i.e. falls or autonomic dysfunction
*PD pts are unable to perform these Activities for daily living (ADLs). They include:
–Mobility (walking, using stairs) –Feeding self –Grooming, personal hygiene –Toileting –Showering/bathing –Continence (bowel and bladder)
*PD pts experience interference to their ADLs in the form of:
•Choking
•Pneumonia
•Falls
(CPF)
Rapid PD disease progression is defined as __.
H and Y stage 3 after 3 years
As the H and Y scale progresses from 1 to 5, there is increasing disability and dependence. H and Y stage 3 refers to __.
Impaired postural reflexes
Physically independent
The ‘ON’ state for PD patients refers to __.
when pt is responding to levodopa
The ‘OFF’ state for PD patients refers to __.
when pt is not responding to levodopa
The H and Y scale assess __. Patients on treatment should be assessed in their __ and __.
- mobility
2. ON and OFF states
Non-motor symptoms of PD may lead to: \_\_ impairment \_\_ symptoms \_\_ disorders \_\_ dysfunction Fatigue Non-motor symptoms are monitored by the UPDRS scale.
- Cognitive
- Psychiatric
- Sleep
- Autonomic
Young-onset PD pts generally have __ disease progression, __ decline and __ motor complications (with treatment).
slower
less cognitive
earlier
__ is a more common initial presentation for young-onset PD vs __ and __ in late-onset
Dystonia
falls and freezing
The use of __ treatment is preferred to levodopa in young-onset PD in order to __
Dopamine agonist
delay onset of levodopa induced motor complications
*The goal of PD management is to __, __ and __. It is not curative and no PD treatment has been shown to be neuroprotective.
Manage symptoms, maintain function/autonomy
*The focus of pharmacological treatment in PD is to increase central dopamine, dopaminergic transmission. There are 4 classes which include:
- Levodopa + DCI
- Dopamine agonists
- COMT inhibitors
- MAO-B inhibitors
Non-pharmacological options for PD patients include:
- __ (Stretching, transfers, posture, walking)
- __ (Mobility aids, home and workplace safety)
- Speech and __
- Surgery
- Physiotherapy
- Occupational therapy
- Swallowing
Correcting imbalances in pathways are a viable pharmacological treatment option, but are not very good in __.
relieving cardinal symptoms of PD
*Levodopa is the most effective drug for treatment of symptoms, especially bradykinesia and rigidity. It is less effective for __, __ and __.
speech, postural reflex and gait disturbances
*Peripheral conversion of levodopa can cause __ and __. Therefore, it makes sense that levodopa has a DDI with alpha blockers as it __, increasing fall risk.
N/V and hypotension
increases postural hypotension
*Levodopa has drug-food interactions, which is __ and __. As a result, the 2 should be spaced 2-4h apart.
lowered absorption with high fat/protein meals and iron
__ of DCI is required to saturate Dopa decarboxylase daily. It does not cross the BBB.
75-100mg
What is the formulation and strength ratio for Sinemet?
25mg Carbidopa : 100mg levodopa (1:4)
25mg Carbidopa : 250mg levodopa (1:10) - SR/CR
What is the formulation and strength ratio for Madopar?
25mg Benserazide : 100mg levodopa (1:4)
25mg Benserazide : 250mg levodopa (1:10)
*Levodopa induced dyskinesias have a usual onset of __.
within 3-5years of initiating treatment
- Levodopa has CNS side effects which include:
- __, sudden sleep onset
- hallucinations and __
drowsiness
psychosis
Since antipsychotics work by decreasing dopaminergic transmission, it makes sense that levodopa (dopamine agonist) can cause __ effects.
psychosis
The unpredictable ‘On’-‘Off’ phenomenon may be more common with __. It is difficult to __ and has been described as “throwing a light switch”.
younger neurologic patients
control with medications
*The ‘wearing off’ effect of levodopa refers to __ (aka decreased ‘ON’ duration). It is associated with __.
- reduced effect before end of dosing interval
2. disease progression
- How can we manage the ‘wearing off’ effect of levodopa?
1. Modify __
2. Replace __
Modify times of administration, and/or
Replace with modified-release preparations at the appropriate time
- How can we manage levodopa induced dyskinesias?
1. add __ or __
2. replace __
- add amantadine or dopamine agonists
2. replace specific doses with modified-release levodopa (at times of day where dyskinesia is more troublesome)
Levodopa dyskinesias are most common at __. They involve Involuntary, uncontrollable twitching, jerking and __ (painful muscle contractions).
Peak doses
Dystonias
*With progression of PD, the response threshold is __ while the dyskinesia threshold is __. This leads to the increase in SEs.
- increased
2. lowered
*Dose adjustments may be needed when switching between immediate-release (IR) and controlled-release (CR) forms because __.
–IR to CR : generally __ doses (~25%-50%)
–CR to IR : generally __doses
Dose adjustments may be limited by __.
- CR dosage forms have lower bioavailability
- increase
- decrease
- available dosage forms
*Controlled-release (CR) levodopa formulations are designed to release levodopa/DCI over a longer period of time, around __. They are more useful for __.
4-6h
stiffness on waking
Some administration precautions to note for Sinemet SR?
Do not crush
Some administration precautions to note for Sinemet CR?
Do not cut
Some administration precautions to note for Madopar HBS?
Do not open capsule
Pyridoxine is a co-factor for dopa decarboxylase. Will interactions be expected between levodopa and pyridoxine use in TB patients?
No, as only low doses are used
Pyridoxine is a co-factor for dopa decarboxylase. Will interactions be expected between levodopa and pyridoxine use in hematological patients?
Yes, as high potency doses are used
*Common anti-emetics such as Metoclopramide and prochlorperazine are __ and will reduce effectiveness of levodopa. The anti-emetic of choice in PD is __.
- anti-dopaminergic drugs (crosses BBB more)
2. domperidone (crosses BBB less)
*Antipsychotics i.e. Risperidone have opposite MOA compared to Levodopa and may cause __ or even __.
EPSEs or even inhibit levodopa action
For foreign travelers, we should note the interaction between levodopa and __ (drug class not stocked in SG) due to its anti-dopaminergic effects.
Non-selective MAO-I
*What are some ergot derivatives of dopamine agonists available in SG?
Pergolide (ergot) Cabergoline Bromocriptine (PECB)
*What are some non-ergot derivatives of dopamine agonists available in SG? – \_\_ – \_\_ – \_\_ (transdermal) – \_\_ (SQ)
(non-ergot) –Pramipexole –Ropinirole –Rotigotine (transdermal) –Apomorphine (SQ) (NEPRRA)
*What are the 3 key clinically important differences between ergot and non-ergot derivatives?
- Lower F for ergot derived due to extensive 1st pass
- Higher fibrosis risk for ergot derived
- Higher Valvular heart disease risk for ergot derived
*Compared to Levodopa, Dopamine agonists have a __ and cause less __.
longer half life/duration of action
less motor complications
*Ropinirole is mainly metabolized via __. Dose adjustments should be made for __.
Hepatic route
hepatic impairment